Management of hepatitis B virus (HBV) infection in multiple sclerosis patients on disease modifying therapies (DMTs)
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) can increase the risk of hepatitis B virus (HBV) reactivation (HBr), particularly with agents like ocrelizumab and alemtuzumab. However, studies in MS patients treated with DMTs indicate significantly lower reactivation rates compared to those with hematologic malignancies. This review discusses strategies for managing HBV in MS patien